cancer therapeutics-related cardiac dysfunction(English)

• defined as a ≥10% absolute decline in LVEF from baseline to a value <50% (or 53%) with or without HF symptoms
• EF, HF, ACC, ADT, BTK, SCT, CTR-CVT, ACHD, AF, AIC, BP, BRAF, BTKi, CAC, CAD, CAR-T, CIED, CLL, CMR, CRS, cTn, cTnI, ECG, GLS, GnRH, HbA1C, HSCT, HER2, ICI, IHD, IMID, LAVI, LVEF, MEK, MM, NT-proBNP, PI, RVEDV, TAPSE, TKI, TTE, VEGFi, ATTR, BPA, CHD, CTEPH, CTR-RVT, EGFR, FAC, FWLS, IE, IVC, MPI, NBTE, NET, PAH, PE, PEA, RAVI, RH, RHC, RHF, RVEF, RVESV, RVLS, RVOT, TIL, TRV, VEGF, VTE
• Cardiology, Oncology, Ratio-based metric
• https://doi.org…3/ehjci/jeaa288
• http://dx.doi.o…cho.2014.07.012
• https://doi.org…cao.2024.07.017
• https://doi.org….1002/ejhf.3412